C4 Therapeutics Q1 Revenue Falls 15%, EPS Loss Narrows to ($0.20)
Summary
C4 Therapeutics announced its first-quarter 2026 financial results, reporting revenue of $6.15 million, a 15% decrease year-over-year, but a notable improvement in diluted loss per share to ($0.20) from ($0.37) in the prior year. The company also reduced its net loss to ($25.13 million). These results, derived from the 10-Q filing, highlight strategic R&D cost management, including project prioritization and the termination of a Merck collaboration, which contributed to the narrowed loss. Additionally, C4 Therapeutics advanced its cemsidomide program into Phase 2 and 1b studies and secured a new research agreement with Roche. For this clinical-stage biotech, the improved burn rate and pipeline progress are critical, and traders will monitor future clinical milestones and the financial impact of ongoing collaborations.
At the time of this announcement, CCCC was trading at $3.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $309.3M. The 52-week trading range was $1.21 to $3.82. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.